Latest studies
- Active not recruitingPHASE3
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
This study is looking at a new treatment called Tarlatamab for advanced small cell lung cancer that has come back after earlier treatment. We want to see if Tarlatamab helps people live longer compared to standard chemotherapy.
Small Cell Lung Cancer (SCLC)Brazil - RecruitingPHASE3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
This study looks at a new combination treatment, Sigvotatug Vedotin plus pembrolizumab, for a type of lung cancer where a protein called PD-L1 is high. We want to see if this combination works better than pembrolizumab alone to help patients.
Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungCarcinoma, Non-Small-Cell Lung (NSCLC)Brazil - Active not recruitingPHASE3
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
This study looks at a new drug, apalutamide, combined with standard hormone therapy for men with high-risk prostate cancer before and after surgery. It aims to see if this combination helps shrink the cancer more and prevents it from spreading, compared to hormone therapy alone.
Prostatic NeoplasmsBrazil - RecruitingPHASE3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is testing a new drug, linvoseltamab, for multiple myeloma that has returned or needs re-treatment. It compares linvoseltamab to a standard three-drug combination (elotuzumab, pomalidomide, and dexamethasone) to see which works better and has fewer side effects.
Relapsed Refractory Multiple Myeloma (RRMM)Brazil - Active not recruitingPHASE3
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
This study is testing a new combination treatment for advanced bowel cancer. It compares a new medicine (S95005) with an existing one (capecitabine), both given with bevacizumab. The aim is to see if the new combination works better for patients who can't have intensive chemotherapy.
Metastatic Colorectal CancerBrazil - Active not recruitingPHASE3
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
This study looks at a new personalised treatment, Intismeran Autogene, combined with Pembrolizumab for high-risk melanoma. It aims to see if this combination can stop cancer from coming back better than Pembrolizumab alone after surgery, focusing on safety and effectiveness.
MelanomaBrazil - Active not recruitingPHASE3
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
This study is testing new drug combinations for a type of kidney cancer called Papillary Renal Cell Carcinoma (PRCC). It compares a mix of savolitinib and durvalumab, or just durvalumab, against a standard treatment, sunitinib, for advanced PRCC linked to a specific genetic change.
Papillary Renal Cell CarcinomaBrazil - Active not recruitingPHASE2
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
This study is testing a new drug called batoclimab for adults with a nerve condition called Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It aims to see how well it works and if it's safe compared to a dummy drug.
Chronic Inflammatory Demyelinating PolyneuropathyBrazil - RecruitingPHASE3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
This study is testing a new medicine, efruxifermin, for people with a serious liver condition called NASH/MASH cirrhosis. It's to see if the medicine helps improve liver health in those with scarring that hasn't yet caused severe problems.
NASH - Nonalcoholic SteatohepatitisMASH - Metabolic Dysfunction-Associated SteatohepatitisBrazil - RecruitingPHASE3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
This study is testing a new medicine, Opevesostat, for men with prostate cancer that has spread and is resistant to hormone treatment. We want to see if Opevesostat helps men live longer compared to standard hormone therapies, especially after they've had other treatments.
Prostate Cancer MetastaticBrazil - RecruitingPHASE3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
This study compares a new medicine, deucravacitinib, with an existing one, ustekinumab, for long-term safety in people with moderate to severe plaque psoriasis. It focuses on participants who also have heart disease risk factors.
Plaque PsoriasisBrazil - RecruitingPHASE3
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
This study is testing a new medicine called Afimkibart for people with moderately to severely active Crohn's disease. It's a Phase 3 study, which means it's a big step before the medicine might become widely available, looking at how well it works and if it's safe.
Moderately to Severely Active Crohns DiseaseBrazil - RecruitingPHASE3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
This study is testing if a new combination of medicines, including tucatinib, works better than current treatments for people with advanced HER2-positive bowel cancer. It also looks at side effects. Participants will be randomly assigned to receive either the new combination or standard care.
Colorectal NeoplasmsBrazil - RecruitingPHASE3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
This study looks at a new medicine called Tozorakimab. We want to see if it can help people in hospital with lung infections who need extra oxygen. The goal is to stop them from getting sicker, like needing a breathing machine, or even dying.
Viral Lung Infection and Acute Respiratory FailureBrazil - RecruitingPHASE3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
This study looks at a new drug, olomorasib, combined with other treatments for advanced lung cancer. It’s for people whose cancer has a specific change called KRAS G12C and haven't had previous treatment for advanced disease. The aim is to see if this new combination works better than standard care.
Carcinoma, Non-Small-Cell LungNeoplasm MetastasisBrazil - Recruiting
Product Surveillance Registry
This study keeps track of how well Medtronic medical devices, like those for heart problems or other conditions, work in real life. It aims to make sure these devices are safe and effective for patients.
Cardiac Rhythm DisordersUrological DisordersNeurological DisordersCardiovascular DisordersBrazil - Active not recruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
This study compares a new medicine, Sacituzumab Tirumotecan, with standard chemotherapy for advanced lung cancer. It’s for people whose cancer has specific genetic changes and has already been treated. We're looking to see if the new medicine helps people live longer and keeps their cancer from growing for longer.
Non-small Cell Lung Cancer (NSCLC)Brazil - Active not recruitingPHASE2
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
This study is looking at a new combination treatment, JNJ-78934804, for people aged 18-65 with Crohn's disease that is moderate to severe. It compares this new treatment to existing medicines, guselkumab and golimumab, to see how well it works over 48 weeks.
Crohn's DiseaseBrazil - Active not recruitingPHASE3
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
This study looks at two different medicines, T-DXd and T-DM1, for certain people with HER2-positive breast cancer. It's for those who still have some cancer after their first treatments. We want to see if T-DXd works better at stopping the cancer from coming back.
HER2-Positive Primary Breast CancerResidual Invasive Breast CancerBrazil - RecruitingPHASE3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
This study looks at the long-term safety of a new medicine, KarXT, for people with changes in their thoughts and feelings due to Alzheimer's disease. Participants have already taken part in similar studies and will continue to be monitored for about a year.
Psychosis Associated With Alzheimer's DiseaseBrazil - Active not recruitingPHASE3
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
This study is looking at a new treatment for men with prostate cancer that has spread and is responding to hormone therapy. It combines a drug called niraparib with standard treatments (abiraterone acetate and prednisone) to see if it works better for those with specific genetic changes.
Metastatic Castration-sensitive Prostate CancerBrazil - RecruitingPHASE3
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This study looks at a new way to give a cancer drug called tislelizumab for advanced stomach cancer. We're comparing injections under the skin to drips into a vein, alongside usual chemotherapy. We want to see if the injection works just as well and is easier for patients.
Metastatic Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaBrazil - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
This study is testing a new combination of medicines, Giredestrant and Palbociclib, for advanced breast cancer. It's for people whose cancer is hormone-sensitive (ER-positive) but not HER2-positive. Researchers want to see if this new combination works better and is safer than a standard treatment.
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerBrazil - Active not recruitingPHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
This study looks at a new combination of drugs, cabozantinib and atezolizumab, for men with prostate cancer that has spread and is no longer responding to hormone therapy. It compares this new combination with standard hormone treatments to see if it works better.
Metastatic Prostate CancerProstate AdenocarcinomaBrazil - Active not recruitingPHASE2
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
This study is testing new immune-based treatments for a type of bladder cancer that has spread. Researchers want to see if combinations of medicines like tobemstomig and tiragolumab are safe and work better than atezolizumab for people who can't have standard chemotherapy.
Urothelial CancerBrazil - Active not recruitingPHASE3
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
This study is comparing two ways of giving a medicine called amivantamab for advanced lung cancer. One is through a drip, and the other is a new injection under the skin. We want to see if the injection is easier and quicker for patients.
Advanced or Metastatic Non-small Cell Lung CancerBrazil - Active not recruitingPHASE2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
This study is for men with prostate cancer who are already taking enzalutamide as part of another research study. It aims to gather more information on the long-term safety of enzalutamide when it's helping them. Participants will continue their current treatment and have regular check-ups.
Prostate CancerBrazil - Active not recruitingPHASE3
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
This study looks at a drug called Olaparib for women with a specific type of ovarian cancer. It's for those whose cancer has improved after chemotherapy and have a change in their BRCA gene. We want to see if Olaparib helps keep the cancer away longer.
Platinum SensitiveBRCA MutatedRelapsed Ovarian CancerFollowing Complete or Partial Response to Platinum Based ChemotherapyBrazil - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
This study looks at a new drug, Giredestrant, combined with an existing treatment called Phesgo, for advanced breast cancer. It aims to see if this new combination is safe and works better than Phesgo alone for people with specific types of breast cancer.
Locally Advanced or Metastatic Breast CancerBrazil - RecruitingPHASE3
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
This study is testing a new medicine, tezepelumab, for adults with moderate to very severe COPD. It wants to see if the medicine helps improve their breathing and overall health, and if it's safe to use.
Chronic Obstructive Pulmonary Disease (COPD)Brazil - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
This study is looking at a new medicine called icotrokinra for people with psoriatic arthritis. We want to see if it helps reduce joint pain and swelling, and if it's safe. Some people will get the new medicine, others a dummy medicine.
Arthritis, PsoriaticBrazil - Active not recruitingPHASE3
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
This study is looking at a new medicine called remibrutinib for people with relapsing multiple sclerosis (RMS). It compares remibrutinib to an existing medicine, teriflunomide, to see how well it works and if it's safe. It's a large study, involving about 800 people.
Relapsing Multiple SclerosisBrazil - RecruitingPHASE3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is looking into a new medicine, BI 1291583, for people with bronchiectasis. It aims to see if this medicine can help reduce flare-ups, which are common with the condition. Participants will take a tablet daily and be monitored for up to 1 year and 8 months.
BronchiectasisBrazil - Active not recruitingPHASE3
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
This study compares a new drug, cabozantinib, with a dummy drug (placebo) for differentiated thyroid cancer that has continued to grow despite previous treatments. It aims to see if cabozantinib can slow down the cancer's progression.
Differentiated Thyroid CancerBrazil - RecruitingPHASE1, PHASE2
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
This study is testing a new drug, Zilovertamab Vedotin, for children and young adults aged 6 months to 25 years with certain blood cancers (like some types of leukaemia and lymphoma) and solid tumours (like neuroblastoma and Ewing sarcoma) that have come back or not responded to previous treatments.
B-cell Acute Lymphoblastic LeukemiaDiffuse Large B-cell LymphomaBurkitt LymphomaNeuroblastomaBrazil - RecruitingPHASE3
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
This study looks at a new treatment called dostarlimab for certain types of colon cancer that haven't spread. It compares dostarlimab with standard treatments to see if it works better before and after surgery to help patients.
Colonic NeoplasmsNeoplasms, ColonBrazil - RecruitingPHASE3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
This study looks at new treatments for a type of breast cancer called triple-negative. It compares a new drug, Dato-DXd, sometimes with Durvalumab, against standard chemotherapy with Pembrolizumab for patients whose cancer has come back locally or spread.
Breast CancerBrazil - Active not recruitingPHASE3
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
This study is looking at a new medicine called Tezepelumab for people aged 12-80 with Eosinophilic Oesophagitis (EoE). It aims to see if regular injections help improve symptoms and is safe, compared to a dummy treatment.
Eosinophilic EsophagitisBrazil - Active not recruitingPHASE2
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
This study looks at a new treatment called trastuzumab deruxtecan (T-DXd) for several types of advanced cancer where a protein called HER2 is present. Researchers want to see how well it works and if it's safe for people with bladder, pancreatic, and other solid tumours.
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal CancerPart 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal CancerBrazil - Active not recruitingPHASE3
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
This study is comparing two drug combinations for advanced melanoma skin cancer: fianlimab plus cemiplimab, and pembrolizumab. It aims to see which is more effective, what side effects occur, and how they affect adults and teenagers.
MelanomaBrazil - RecruitingPHASE3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
This study compares a new medicine, opevesostat, with existing treatments like abiraterone or enzalutamide for prostate cancer that has spread and is no longer responding well to standard hormone therapy. It aims to see if opevesostat is safer and more effective at stopping cancer growth.
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic NeoplasmsBrazil - Enrolling by invitationPHASE3
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
This study looks at the long-term effects and safety of a drug called Ralinepag for people with a lung condition called pulmonary arterial hypertension (PAH). It's for those who have already tried Ralinepag in a previous study.
PAHPulmonary HypertensionPulmonary Arterial HypertensionHypertensionBrazil - Active not recruitingPHASE3
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
This study looks at the long-term safety and effectiveness of a new medicine, ianalumab, for people with Sjögren's Syndrome. It's for those who have already completed an earlier study and aims to see how well the treatment works and if it has any long-term side effects.
Sjogrens SyndromeBrazil - RecruitingPHASE3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study looks at a new medicine, vicadrostat, for people with type 2 diabetes, high blood pressure, and heart disease. It aims to see if taking vicadrostat alongside empagliflozin can help reduce heart problems. Half the participants will get the study medicine, and half will get a dummy pill.
Diabetes Mellitus, Type 2HypertensionCardiovascular DiseasesBrazil - Active not recruitingPHASE3
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
This study looks at new drug combinations for advanced breast cancer that has grown despite previous treatments. It compares different medications, including gedatolisib, fulvestrant, and palbociclib, to see if they are safe and effective.
Breast CancerBrazil - Active not recruitingPHASE3
A Study of Zigakibart in Adults With IgA Nephropathy
This study is testing a new medicine, BION-1301, for adults with IgA Nephropathy to see if it can help their kidneys. It compares the new medicine to a dummy medicine (placebo).
IgA NephropathyImmunoglobulin A NephropathyBrazil - RecruitingPHASE3
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
This study is looking at a new medicine called nipocalimab for adults with moderate to severe lupus. It compares nipocalimab to a dummy treatment (placebo) to see if it can help reduce inflammation and improve lupus symptoms.
Lupus Erythematosus, SystemicBrazil - Active not recruitingPHASE3
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
This study looks at a new drug called tucatinib for HER2-positive breast cancer that has spread. We want to see if adding tucatinib to standard treatments (trastuzumab and pertuzumab) helps more than a dummy pill (placebo). It also checks for side effects.
HER2 Positive Breast CancerBrazil - Active not recruitingPHASE3
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
This study looks at a new tablet treatment, upadacitinib, for adults with moderate to severe lupus. It checks how safe and effective the medicine is and aims to reduce symptoms. Some people will get the active drug, others a dummy pill.
Systemic Lupus ErythematosusBrazil - RecruitingPHASE2
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
This study is looking into a new medicine called Volrustomig for various advanced cancers, including cervical, head and neck, oesophageal, and mesothelioma. It aims to see how well it works and if it's safe, both on its own and with standard chemotherapy.
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)Brazil